Efficacy of a morantel sustained-release bolus for control of gastrointestinal parasites in winter-grazed steers in Mississippi.
From Nov 22, 1983 through May 15, 1984, 36 crossbred steers were allotted into 3 treatment groups (12/group) and were grazed on separate 3.4-hectare pastures. On Nov 22, 1983, the steers were administered a single morantel sustained-release bolus (MSRB), orally (group 1), or a single dose of thiabendazole (TBZ; 66 mg/kg of body weight, orally; group 2), or were left untreated (group 3; controls). Animal weights, nematode egg counts in fecal specimens, and plasma pepsinogen concentrations were monitored monthly. At the termination of the study, 4 steers from each treatment group were slaughtered and necropsied and worm counts were determined. A set of parasite-free tracer calves (3/treatment group) were grazed with each treatment group for 1 month, beginning on Nov 22, 1983; a second set of tracer calves (3/group) were grazed with each treatment group for 1 month, beginning Apr 3, 1984. At the end of their respective grazing periods, tracer calves were held for 3 weeks and then were slaughtered and necropsied and their worm counts were determined. Mean nematode egg counts in fecal specimens of group 1 (MSRB treated) were significantly lower (P less than 0.05) than that of the TBZ-treated or nontreated steers. Differences in worm counts were not found between treatment groups. Differences in worm counts of tracer calves were not found among the 3 groups for November 1983 nor for April 1984. Steers treated with the MSRB had a higher mean weight gain (P less than 0.06) than did the control or TBZ-treated steers.
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000469:parasitology* / Q000517:prevention & control; D003692:Delayed-Action Preparations; D005767:Gastrointestinal Diseases / Q000469:parasitology / Q000517:prevention & control / Q000662:veterinary*; D007411:Intestinal Diseases, Parasitic / Q000517:prevention & control / Q000662:veterinary; D008297:Male; D008922:Mississippi; D009015:Morantel / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013827:Thiabendazole / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D011743:Pyrimidines; D009015:Morantel; D013827:Thiabendazole